A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Caitlyn T SolemTimothy J BellYoungmin KwonJoseph C CappelleriCourtney JohnsonHelen BhattacharyyaCaroline J HoangJorge E CortesPublished in: Cancer (2020)
These results suggest that most of the survival benefit from glasdegib plus LDAC versus LDAC alone is TWiST, and this represents added time in relatively "good" health. These results support the clinical value of glasdegib plus LDAC as initial therapy for AML in patients for whom intensive chemotherapy is not an option.
Keyphrases
- acute myeloid leukemia
- low dose
- high dose
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- newly diagnosed
- healthcare
- ejection fraction
- public health
- chronic kidney disease
- prognostic factors
- locally advanced
- mental health
- radiation therapy
- depressive symptoms
- patient reported outcomes
- health information
- signaling pathway
- social media
- physical activity
- chemotherapy induced